Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) EBITDA (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed EBITDA for 13 consecutive years, with -$164000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 96.76% year-over-year to -$164000.0, compared with a TTM value of -$197.2 million through Dec 2025, down 98.48%, and an annual FY2025 reading of -$197.2 million, down 98.48% over the prior year.
  • EBITDA was -$164000.0 for Q4 2025 at Tandem Diabetes Care, up from -$19.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $10.2 million in Q4 2021 and bottomed at -$128.5 million in Q1 2025.
  • Average EBITDA over 5 years is -$29.9 million, with a median of -$18.9 million recorded in 2024.
  • The sharpest move saw EBITDA soared 162.4% in 2021, then tumbled 960.91% in 2022.
  • Year by year, EBITDA stood at $10.2 million in 2021, then crashed by 223.86% to -$12.6 million in 2022, then tumbled by 109.64% to -$26.4 million in 2023, then surged by 80.85% to -$5.1 million in 2024, then surged by 96.76% to -$164000.0 in 2025.
  • Business Quant data shows EBITDA for TNDM at -$164000.0 in Q4 2025, -$19.7 million in Q3 2025, and -$48.7 million in Q2 2025.